發送短信 : Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

 _____      _____     _____      ___      _____   
|  __ \\   |  ___||  |__  //    / _ \\   |__  //  
| |  \ ||  | ||__      / //    / //\ \\    / //   
| |__/ ||  | ||__     / //__  |  ___  ||  / //__  
|_____//   |_____||  /_____|| |_||  |_|| /_____|| 
 -----`    `-----`   `-----`  `-`   `-`  `-----`